Pharmanutra S.p.A. (761.F)
- Previous Close
49.65 - Open
49.20 - Bid 50.00 x --
- Ask 51.60 x --
- Day's Range
49.20 - 49.60 - 52 Week Range
45.00 - 60.30 - Volume
6 - Avg. Volume
0 - Market Cap (intraday)
482.891M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
29.01 - EPS (TTM)
1.71 - Earnings Date May 12, 2025
- Forward Dividend & Yield 1.00 (2.01%)
- Ex-Dividend Date May 5, 2025
- 1y Target Est
--
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It also offers iron deficiency, inflammation, mineral and vitamin, muscle and joint, sports nutrition, ophthalmic, and night rest products; and medical instrumentation and software for body bioimpedance analysis. The company sells its products through sales representatives, wholesalers, pharmacies, para-pharmacies, agents, distributors, online sales, local partners, and tenders. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
www.pharmanutra.it118
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 761.F
View MorePerformance Overview: 761.F
Trailing total returns as of 6/2/2025, which may include dividends or other distributions. Benchmark is FTSE MIB Index (FTSEMIB.MI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 761.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 761.F
View MoreValuation Measures
Market Cap
479.06M
Enterprise Value
472.36M
Trailing P/E
29.04
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.99
Price/Book (mrq)
7.39
Enterprise Value/Revenue
3.95
Enterprise Value/EBITDA
14.70
Financial Highlights
Profitability and Income Statement
Profit Margin
14.30%
Return on Assets (ttm)
14.88%
Return on Equity (ttm)
28.39%
Revenue (ttm)
116.15M
Net Income Avi to Common (ttm)
16.61M
Diluted EPS (ttm)
1.71
Balance Sheet and Cash Flow
Total Cash (mrq)
29.1M
Total Debt/Equity (mrq)
39.02%
Levered Free Cash Flow (ttm)
12.86M